BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 31283600)

  • 21.
    Uprimny C; Kroiss AS; Decristoforo C; Fritz J; von Guggenberg E; Kendler D; Scarpa L; di Santo G; Roig LG; Maffey-Steffan J; Horninger W; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):941-949. PubMed ID: 28138747
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patterns of Progression After
    Soldatov A; von Klot CAJ; Walacides D; Derlin T; Bengel FM; Ross TL; Wester HJ; Derlin K; Kuczyk MA; Christiansen H; Henkenberens C
    Int J Radiat Oncol Biol Phys; 2019 Jan; 103(1):95-104. PubMed ID: 30201438
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of [
    Frenzel T; Tienken M; Abel M; Berliner C; Klutmann S; Beyersdorff D; Schwarz R; Krüll A; Bannas P
    Strahlenther Onkol; 2018 Jul; 194(7):646-654. PubMed ID: 29572670
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The feasibility of prostate-specific membrane antigen positron emission tomography(PSMA PET/CT)-guided radiotherapy in oligometastatic prostate cancer patients.
    Guler OC; Engels B; Onal C; Everaert H; Van den Begin R; Gevaert T; de Ridder M
    Clin Transl Oncol; 2018 Apr; 20(4):484-490. PubMed ID: 28795303
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of
    Walacides D; Meier A; Knöchelmann AC; Meinecke D; Derlin T; Bengel FM; Ross TL; Wester HJ; Derlin K; Kuczyk MA; von Klot CAJ; Christiansen H; Henkenberens C
    Strahlenther Onkol; 2019 May; 195(5):420-429. PubMed ID: 30610354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of
    Ferraro DA; Garcia Schüler HI; Muehlematter UJ; Eberli D; Müller J; Müller A; Gablinger R; Kranzbühler H; Omlin A; Kaufmann PA; Hermanns T; Burger IA
    Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):652-664. PubMed ID: 31802175
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of
    Sonni I; Eiber M; Fendler WP; Alano RM; Vangala SS; Kishan AU; Nickols N; Rettig MB; Reiter RE; Czernin J; Calais J
    J Nucl Med; 2020 Aug; 61(8):1153-1160. PubMed ID: 31924715
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinicopathological predictors of positive
    Aydin AM; Haberal B; Artykov M; Bilen CY; Yazici S
    Ann Nucl Med; 2019 May; 33(5):326-332. PubMed ID: 30778860
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Pfister D; Haidl F; Nestler T; Verburg F; Schmidt M; Wittersheim M; Steib F; Heidenreich A
    BJU Int; 2020 Dec; 126(6):679-683. PubMed ID: 32531840
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MRI versus ⁶⁸Ga-PSMA PET/CT for gross tumour volume delineation in radiation treatment planning of primary prostate cancer.
    Zamboglou C; Wieser G; Hennies S; Rempel I; Kirste S; Soschynski M; Rischke HC; Fechter T; Jilg CA; Langer M; Meyer PT; Bock M; Grosu AL
    Eur J Nucl Med Mol Imaging; 2016 May; 43(5):889-897. PubMed ID: 26592938
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    Lengana T; Lawal IO; Boshomane TG; Popoola GO; Mokoala KMG; Moshokoa E; Maes A; Mokgoro NP; Van de Wiele C; Vorster M; Sathekge MM
    Clin Genitourin Cancer; 2018 Oct; 16(5):392-401. PubMed ID: 30120038
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of Staging
    Wu SY; Boreta L; Shinohara K; Nguyen H; Gottschalk AR; Hsu IC; Roach M; Westphalen AC; Feng FY; Carroll PR; Chang AJ; Hope TA
    Urology; 2019 Mar; 125():154-162. PubMed ID: 30580002
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is there a utility of adding skeletal imaging to 68-Ga-prostate-specific membrane antigen-PET/computed tomography in initial staging of patients with high-risk prostate cancer?
    Raju S; Sharma A; Patel C; Sahoo R; Das CJ; Kumar S; Sharma A; Kumar R
    Nucl Med Commun; 2020 Nov; 41(11):1183-1188. PubMed ID: 32796451
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    Vinsensia M; Chyoke PL; Hadaschik B; Holland-Letz T; Moltz J; Kopka K; Rauscher I; Mier W; Schwaiger M; Haberkorn U; Mauer T; Kratochwil C; Eiber M; Giesel FL
    J Nucl Med; 2017 Dec; 58(12):1949-1955. PubMed ID: 28637799
    [No Abstract]   [Full Text] [Related]  

  • 35. Correlations of the
    Karyagar SS; Karyagar S; Guven O
    Hell J Nucl Med; 2020; 23(2):120-124. PubMed ID: 32716402
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Focal dose escalation for prostate cancer using
    Zamboglou C; Thomann B; Koubar K; Bronsert P; Krauss T; Rischke HC; Sachpazidis I; Drendel V; Salman N; Reichel K; Jilg CA; Werner M; Meyer PT; Bock M; Baltas D; Grosu AL
    Radiat Oncol; 2018 May; 13(1):81. PubMed ID: 29716617
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.
    Schmidkonz C; Cordes M; Goetz TI; Prante O; Kuwert T; Ritt P; Uder M; Wullich B; Goebell P; Bäuerle T
    Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection Efficacy of Hybrid
    Einspieler I; Rauscher I; Düwel C; Krönke M; Rischpler C; Habl G; Dewes S; Ott A; Wester HJ; Schwaiger M; Maurer T; Eiber M
    J Nucl Med; 2017 Jul; 58(7):1081-1087. PubMed ID: 28209912
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparing the Staging/Restaging Performance of 68Ga-Labeled Prostate-Specific Membrane Antigen and 18F-Choline PET/CT in Prostate Cancer: A Systematic Review and Meta-analysis.
    Lin CY; Lee MT; Lin CL; Kao CH
    Clin Nucl Med; 2019 May; 44(5):365-376. PubMed ID: 30888999
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.
    Schmidt-Hegemann NS; Fendler WP; Buchner A; Stief C; Rogowski P; Niyazi M; Eze C; Li M; Bartenstein P; Belka C; Ganswindt U
    Radiat Oncol; 2017 Nov; 12(1):176. PubMed ID: 29126446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.